Synergy Innovation Co (048870) Fair Value & Analysis
Healthcare · KR · Market cap 137B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 19 days ago
Share price +1.7% over the past month.
Below-average quality, and screening another 13% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,480 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (619.72 KRW to 1,480 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,445 KRW – 6,320 KRW · fair‑value band 619.72 KRW – 1,480 KRW · the 1,708 KRW price screens above the 1,480 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Synergy Innovation Co (048870) currently trades at 1,708 KRW, while our model-based Fair Value estimate is 1,480 KRW, implying the stock looks roughly 13.4% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Synergy Innovation Co generated revenue of 113B KRW at a net margin of 5.4%. Revenue declined 0.8% year over year. It earns a return on equity of 5.6%. Net debt stands at 31.6B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 619.72 KRW (bear case) to 1,480 KRW (bull case); at 1,708 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -13%, 048870 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth DCF (3,273 KRW) versus Earnings-Based (611.45 KRW). Highest evidence: Growth DCF (80).
Notify me when 048870 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Synergy Innovation Co., Ltd. engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea.
Full company description
Synergy Innovation Co., Ltd. engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea. It produces and sells various culture media for hospitals, pharmaceuticals, and food/cosmetics; manufactures synergy innovation " universal transport solutions (SI-UTS); and invests and develops in various fields comprising microorganism, bacteria, and virus. The company also provides pharmaceutical formulations; and develops non-vascular stents. Synergy Innovation Co., Ltd. was founded in 1998 and is headquartered in Seongnam-Si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Synergy Innovation Co reported revenue of 113B KRW in FY2025 versus 30.7B KRW in FY2021, a compound +38.5%/yr. Reported net income was 3.0B KRW in FY2025, compounding −14.8%/yr from FY2021.
048870 screens 13% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Synergy Innovation Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Synergy Innovation Co (048870) overvalued or undervalued?
What is the fair value of 048870?
What is the quality score of 048870?
What is the revenue of Synergy Innovation Co (048870)?
What is the net profit margin of 048870?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Synergy Innovation Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.